News

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

Although antibodies normally shield us from infection, a new study suggests that certain maternal antibodies may actually make it easier for Zika virus to gain a foothold and cause birth defects.

The first Contagion® Connect podcast features a conversation with Dr. Alexandra Phelan about the impact of pandemic bonds in the ongoing Ebola outbreak in the DRC.

A new report on US prescribing trends and stewardship initiatives assesses the scope of the antibiotic resistance problem and lays the groundwork for solutions.

Lactic acid produced by bacteria in the vagina may help protect women from Chlamydia trachomatis infection, a new study suggests.

Parents seeking medical exclusions for their children must now have their physician fill out a state form explaining specifically why the exemption is warranted.

A recent study provides what may be the first in-depth examination of the molecular mechanism of biotransformation of a large number of orally administered agents by the human gut microbiota.

Variances in collection and siloed efforts are hurting this outbreak response.

A research team’s latest study offers new insights into a weak point on the Lassa virus surface and the neutralizing antibodies capable of targeting it.

Both the oral and intravenous formulations of the novel pleuromutilin antibiotic were shown to be efficacious in 2 phase 3 studies.

The HITS consortium provided a wealth of knowledge on infection prevention topics, but also served as an environment for frank and honest discussions regarding Legionella management.

Daptomycin plus β-lactam therapy was associated with reduced composite definition for clinical failure but, worryingly, was also linked to increased risk of acute kidney injury.

The vaccine was based on a recombinant protein subunit (CTH522) and evaluated in a prime-boost immunization schedule.

Here is a look at infectious disease-related US Food and Drug Administration news from the week of August 11, 2019.

We’ve rounded up a list of important US Food and Drug Administration and US Department of Agriculture recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Evidence demonstrates that antimicrobial therapy with an anti-staphylococcal β-lactam antibiotic is the gold standard for treatment of SAB caused by MSSA, but confusion about which agent—particularly cefazolin versus an anti-staphylococcal penicillin—is preferred remains an unanswered question

The CDC hopes the case of a patient who was hospitalized in Maryland following a hospitalization in Kenya will help raise awareness of the importance of C auris screening.

Transitioning from a child born with HIV into an adult living with HIV often means less adherence to antiretroviral medication therapies and a lower level of viral suppression. A new study delves into some possible reasons why.

As outbreaks of vaccine-preventable diseases grow, it is important to review vaccination recommendations by age group.

Patients and health care professionals alike cite significant issues with education and emotion surrounding MDROs.

The research team deciphered that the nitazoxanide boosts the ability of specific viral sensors to detect Ebola when infected, which then sparks an antiviral immune response.

The approval marks the second drug approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

In total, 24 Massachusetts communities are now considered high risk for EEE virus and 18 communities have been designated to be at moderate risk.

Changes to Medicare funding, reimbursement, and proposed new legislation highlight new initiatives as investigators gain a better understanding of multidrug-resistant organism transmission.

Sterilization by radiation plus infection with Wolbachia bacteria in male mosquitoes can go a long way toward lowering the burden of deadly disease.

Investigators in the first human trial of a MERS-CoV candidate report strong immune responses and no serious adverse events, advancing the vaccine candidate to phase 1/2a and phase 2 trials.

We're failing to make sure cultures are indicated properly in catheterized patients, which can lead to serious disruptions of care.

The NIH-funded study will evaluate experimental adjuvants AF03 and Advax-CpG55.2 over an 18-month study period.

Research on a tenofovir disoproxil fumarate intravaginal ring for PrEP hit a hurdle when 8 of 12 women unexpectedly developed vaginal ulcers.